Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 57

1.

Interreader Variability of Dynamic Contrast-enhanced MRI of Recurrent Glioblastoma: The Multicenter ACRIN 6677/RTOG 0625 Study.

Barboriak DP, Zhang Z, Desai P, Snyder BS, Safriel Y, McKinstry RC, Bokstein F, Sorensen G, Gilbert MR, Boxerman JL.

Radiology. 2018 Nov 27:181296. doi: 10.1148/radiol.2019181296. [Epub ahead of print]

PMID:
30480488
2.

Myelin water fraction changes in febrile seizures.

Moldovan K, Boxerman JL, O'Muircheartaigh J, Dean D, Eyerly-Webb S, Cosgrove GR, Pucci FG, Deoni SCL, Spader HS.

Clin Neurol Neurosurg. 2018 Dec;175:61-67. doi: 10.1016/j.clineuro.2018.10.005. Epub 2018 Oct 10.

PMID:
30384118
3.

Optimization of Acquisition and Analysis Methods for Clinical Dynamic Susceptibility Contrast MRI Using a Population-Based Digital Reference Object.

Semmineh NB, Bell LC, Stokes AM, Hu LS, Boxerman JL, Quarles CC.

AJNR Am J Neuroradiol. 2018 Nov;39(11):1981-1988. doi: 10.3174/ajnr.A5827. Epub 2018 Oct 11.

PMID:
30309842
4.

Group A streptococcus acute otitis media progressing to neuroinvasive disease in adults.

Patel KM, Johnson JE, Boxerman JL, Nau GJ.

IDCases. 2018 May 23;12:161-164. doi: 10.1016/j.idcr.2018.05.012. eCollection 2018.

5.

First confirmed case of Powassan neuroinvasive disease in Rhode Island.

Patel KM, Johnson J, Zacharioudakis IM, Boxerman JL, Flanigan TP, Reece RM.

IDCases. 2018 Mar 23;12:84-87. doi: 10.1016/j.idcr.2018.03.016. eCollection 2018.

6.

Prognostic value of contrast enhancement and FLAIR for survival in newly diagnosed glioblastoma treated with and without bevacizumab: results from ACRIN 6686.

Boxerman JL, Zhang Z, Safriel Y, Rogg JM, Wolf RL, Mohan S, Marques H, Sorensen AG, Gilbert MR, Barboriak DP.

Neuro Oncol. 2018 Sep 3;20(10):1400-1410. doi: 10.1093/neuonc/noy049.

PMID:
29590461
7.

A Population-Based Digital Reference Object (DRO) for Optimizing Dynamic Susceptibility Contrast (DSC)-MRI Methods for Clinical Trials.

Semmineh NB, Stokes AM, Bell LC, Boxerman JL, Quarles CC.

Tomography. 2017 Mar;3(1):41-49. doi: 10.18383/j.tom.2016.00286.

8.

Pseudoprogression, radionecrosis, inflammation or true tumor progression? challenges associated with glioblastoma response assessment in an evolving therapeutic landscape.

Ellingson BM, Chung C, Pope WB, Boxerman JL, Kaufmann TJ.

J Neurooncol. 2017 Sep;134(3):495-504. doi: 10.1007/s11060-017-2375-2. Epub 2017 Apr 5. Review.

10.

Toxoplasmosis versus lymphoma: Cerebral lesion characterization using DSC-MRI revisited.

Dibble EH, Boxerman JL, Baird GL, Donahue JE, Rogg JM.

Clin Neurol Neurosurg. 2017 Jan;152:84-89. doi: 10.1016/j.clineuro.2016.11.023. Epub 2016 Dec 2.

PMID:
27940418
11.

Dynamic Susceptibility Contrast MR Imaging in Glioma: Review of Current Clinical Practice.

Boxerman JL, Shiroishi MS, Ellingson BM, Pope WB.

Magn Reson Imaging Clin N Am. 2016 Nov;24(4):649-670. doi: 10.1016/j.mric.2016.06.005. Epub 2016 Sep 14. Review.

PMID:
27742108
12.

Management of Craniosynostosis at an Advanced Age: Controversies, Clinical Findings, and Surgical Treatment.

Iyengar RJ, Klinge PM, Chen WS, Boxerman JL, Sullivan SR, Taylor HO.

J Craniofac Surg. 2016 Jul;27(5):e435-41. doi: 10.1097/SCS.0000000000002725.

PMID:
27380569
13.

Improved Leakage Correction for Single-Echo Dynamic Susceptibility Contrast Perfusion MRI Estimates of Relative Cerebral Blood Volume in High-Grade Gliomas by Accounting for Bidirectional Contrast Agent Exchange.

Leu K, Boxerman JL, Cloughesy TF, Lai A, Nghiemphu PL, Liau LM, Pope WB, Ellingson BM.

AJNR Am J Neuroradiol. 2016 Aug;37(8):1440-6. doi: 10.3174/ajnr.A4759. Epub 2016 Apr 14.

14.

Bidirectional Contrast agent leakage correction of dynamic susceptibility contrast (DSC)-MRI improves cerebral blood volume estimation and survival prediction in recurrent glioblastoma treated with bevacizumab.

Leu K, Boxerman JL, Lai A, Nghiemphu PL, Pope WB, Cloughesy TF, Ellingson BM.

J Magn Reson Imaging. 2016 Nov;44(5):1229-1237. doi: 10.1002/jmri.25227. Epub 2016 Mar 12.

15.

PPX and Concurrent Radiation for Newly Diagnosed Glioblastoma Without MGMT Methylation: A Randomized Phase II Study: BrUOG 244.

Elinzano H, Glantz M, Mrugala M, Kesari S, Piccioni DE, Kim L, Pan E, Yunus S, Coyle T, Timothy K, Evans D, Mantripragada K, Boxerman J, DiPetrillo T, Donahue JE, Hebda N, Mitchell KM, Rosati KL, Safran H.

Am J Clin Oncol. 2018 Feb;41(2):159-162. doi: 10.1097/COC.0000000000000247.

PMID:
26658237
16.

Physiologic MRI for assessment of response to therapy and prognosis in glioblastoma.

Shiroishi MS, Boxerman JL, Pope WB.

Neuro Oncol. 2016 Apr;18(4):467-78. doi: 10.1093/neuonc/nov179. Epub 2015 Sep 12. Review.

17.

Dynamic susceptibility contrast MRI measures of relative cerebral blood volume continue to show promise as an early response marker in the setting of bevacizumab treatment.

Boxerman JL, Schmainda KM, Zhang Z, Barboriak DP.

Neuro Oncol. 2015 Nov;17(11):1538-9. doi: 10.1093/neuonc/nov163. Epub 2015 Sep 11. No abstract available.

18.

Standardized Brain Tumor Imaging Protocol for Clinical Trials.

Goldmacher GV, Ellingson BM, Boxerman J, Barboriak D, Pope WB, Gilbert M.

AJNR Am J Neuroradiol. 2015 Oct;36(10):E65-6. doi: 10.3174/ajnr.A4544. Epub 2015 Sep 10. No abstract available.

19.

Consensus recommendations for a standardized Brain Tumor Imaging Protocol in clinical trials.

Ellingson BM, Bendszus M, Boxerman J, Barboriak D, Erickson BJ, Smits M, Nelson SJ, Gerstner E, Alexander B, Goldmacher G, Wick W, Vogelbaum M, Weller M, Galanis E, Kalpathy-Cramer J, Shankar L, Jacobs P, Pope WB, Yang D, Chung C, Knopp MV, Cha S, van den Bent MJ, Chang S, Yung WK, Cloughesy TF, Wen PY, Gilbert MR; Jumpstarting Brain Tumor Drug Development Coalition Imaging Standardization Steering Committee.

Neuro Oncol. 2015 Sep;17(9):1188-98. doi: 10.1093/neuonc/nov095. Epub 2015 Aug 5. Review.

20.

Response Assessment and Magnetic Resonance Imaging Issues for Clinical Trials Involving High-Grade Gliomas.

Boxerman JL, Ellingson BM.

Top Magn Reson Imaging. 2015 Jun;24(3):127-36. doi: 10.1097/RMR.0000000000000054. Review.

PMID:
26049816
21.

ASFNR recommendations for clinical performance of MR dynamic susceptibility contrast perfusion imaging of the brain.

Welker K, Boxerman J, Kalnin A, Kaufmann T, Shiroishi M, Wintermark M; American Society of Functional Neuroradiology MR Perfusion Standards and Practice Subcommittee of the ASFNR Clinical Practice Committee.

AJNR Am J Neuroradiol. 2015 Jun;36(6):E41-51. doi: 10.3174/ajnr.A4341. Epub 2015 Apr 23.

22.

Diffusion MRI quality control and functional diffusion map results in ACRIN 6677/RTOG 0625: a multicenter, randomized, phase II trial of bevacizumab and chemotherapy in recurrent glioblastoma.

Ellingson BM, Kim E, Woodworth DC, Marques H, Boxerman JL, Safriel Y, McKinstry RC, Bokstein F, Jain R, Chi TL, Sorensen AG, Gilbert MR, Barboriak DP.

Int J Oncol. 2015 May;46(5):1883-92. doi: 10.3892/ijo.2015.2891. Epub 2015 Feb 11.

23.

Dynamic susceptibility contrast MRI measures of relative cerebral blood volume as a prognostic marker for overall survival in recurrent glioblastoma: results from the ACRIN 6677/RTOG 0625 multicenter trial.

Schmainda KM, Zhang Z, Prah M, Snyder BS, Gilbert MR, Sorensen AG, Barboriak DP, Boxerman JL.

Neuro Oncol. 2015 Aug;17(8):1148-56. doi: 10.1093/neuonc/nou364. Epub 2015 Feb 2.

24.

Longitudinal DSC-MRI for Distinguishing Tumor Recurrence From Pseudoprogression in Patients With a High-grade Glioma.

Boxerman JL, Ellingson BM, Jeyapalan S, Elinzano H, Harris RJ, Rogg JM, Pope WB, Safran H.

Am J Clin Oncol. 2017 Jun;40(3):228-234. doi: 10.1097/COC.0000000000000156.

PMID:
25436828
25.

Ipilimumab treatment associated pituitary hypophysitis: clinical presentation and imaging diagnosis.

Chodakiewitz Y, Brown S, Boxerman JL, Brody JM, Rogg JM.

Clin Neurol Neurosurg. 2014 Oct;125:125-30. doi: 10.1016/j.clineuro.2014.06.011. Epub 2014 Jul 29. Review.

PMID:
25127260
26.

Principles of T2 *-weighted dynamic susceptibility contrast MRI technique in brain tumor imaging.

Shiroishi MS, Castellazzi G, Boxerman JL, D'Amore F, Essig M, Nguyen TB, Provenzale JM, Enterline DS, Anzalone N, Dörfler A, Rovira À, Wintermark M, Law M.

J Magn Reson Imaging. 2015 Feb;41(2):296-313. doi: 10.1002/jmri.24648. Epub 2014 May 12. Review.

PMID:
24817252
27.

An efficient computational approach to characterize DSC-MRI signals arising from three-dimensional heterogeneous tissue structures.

Semmineh NB, Xu J, Boxerman JL, Delaney GW, Cleary PW, Gore JC, Quarles CC.

PLoS One. 2014 Jan 8;9(1):e84764. doi: 10.1371/journal.pone.0084764. eCollection 2014.

28.

Early post-bevacizumab progression on contrast-enhanced MRI as a prognostic marker for overall survival in recurrent glioblastoma: results from the ACRIN 6677/RTOG 0625 Central Reader Study.

Boxerman JL, Zhang Z, Safriel Y, Larvie M, Snyder BS, Jain R, Chi TL, Sorensen AG, Gilbert MR, Barboriak DP.

Neuro Oncol. 2013 Jul;15(7):945-54. doi: 10.1093/neuonc/not049. Epub 2013 Jun 19.

29.

Prenatal MRI characterization of brainstem glioma.

Swenson DW, Nickel BJ, Boxerman JL, Klinge PM, Rogg JM.

Pediatr Radiol. 2013 Oct;43(10):1404-7. doi: 10.1007/s00247-013-2706-1. Epub 2013 May 16.

PMID:
23677423
30.

Magnetic resonance spectroscopy as an early indicator of response to anti-angiogenic therapy in patients with recurrent glioblastoma: RTOG 0625/ACRIN 6677.

Ratai EM, Zhang Z, Snyder BS, Boxerman JL, Safriel Y, McKinstry RC, Bokstein F, Gilbert MR, Sorensen AG, Barboriak DP.

Neuro Oncol. 2013 Jul;15(7):936-44. doi: 10.1093/neuonc/not044. Epub 2013 May 3.

31.

Advances in myelin imaging with potential clinical application to pediatric imaging.

Spader HS, Ellermeier A, O'Muircheartaigh J, Dean DC 3rd, Dirks H, Boxerman JL, Cosgrove GR, Deoni SC.

Neurosurg Focus. 2013 Apr;34(4):E9. doi: 10.3171/2013.1.FOCUS12426. Review.

32.

The effect of pulse sequence parameters and contrast agent dose on percentage signal recovery in DSC-MRI: implications for clinical applications.

Boxerman JL, Paulson ES, Prah MA, Schmainda KM.

AJNR Am J Neuroradiol. 2013 Jul;34(7):1364-9. doi: 10.3174/ajnr.A3477. Epub 2013 Feb 14.

33.

Paclitaxel poliglumex, temozolomide, and radiation for newly diagnosed high-grade glioma: a Brown University Oncology Group Study.

Jeyapalan S, Boxerman J, Donahue J, Goldman M, Kinsella T, Dipetrillo T, Evans D, Elinzano H, Constantinou M, Stopa E, Puthawala Y, Cielo D, Santaniello A, Oyelese A, Mantripragada K, Rosati K, Isdale D, Safran H; Brown University Oncology Group Study.

Am J Clin Oncol. 2014 Oct;37(5):444-9. doi: 10.1097/COC.0b013e31827de92b.

PMID:
23388562
34.

Radiation necrosis of a high-grade glioma.

Raghavan D, Boxerman J, Jeyapalan S, Rogg J.

Med Health R I. 2012 May;95(5):159-60. No abstract available.

PMID:
22808637
35.

Clinical stroke penumbra: use of National Institutes of Health stroke scale as a surrogate for CT perfusion in patient triage for intra-arterial middle cerebral artery stroke therapy.

Boxerman JL, Jayaraman MV, Mehan WA, Rogg JM, Haas RA.

AJNR Am J Neuroradiol. 2012 Nov;33(10):1893-900. doi: 10.3174/ajnr.A3102. Epub 2012 May 24.

36.

Glioblastoma multiforme: utilization of advanced MRI techniques for preoperative planning.

Raghavan D, Boxerman J, Rogg J, Cosgrove R.

Med Health R I. 2012 Feb;95(2):42-3. No abstract available.

PMID:
22474872
37.

Incidence of extrinsic compression of the internal jugular vein in unselected patients undergoing CT angiography.

Jayaraman MV, Boxerman JL, Davis LM, Haas RA, Rogg JM.

AJNR Am J Neuroradiol. 2012 Aug;33(7):1247-50. doi: 10.3174/ajnr.A2953. Epub 2012 Feb 9.

38.

The Role of preload and leakage correction in gadolinium-based cerebral blood volume estimation determined by comparison with MION as a criterion standard.

Boxerman JL, Prah DE, Paulson ES, Machan JT, Bedekar D, Schmainda KM.

AJNR Am J Neuroradiol. 2012 Jun;33(6):1081-7. doi: 10.3174/ajnr.A2934. Epub 2012 Feb 9.

39.

Cortical blindness following a near-drowning incident.

Koo EH, Boxerman JL, Murphy MA.

J Neuroophthalmol. 2011 Dec;31(4):347-9. doi: 10.1097/WNO.0b013e318228dc87.

PMID:
21775894
40.

Preoperative MRI evaluation of pituitary macroadenoma: imaging features predictive of successful transsphenoidal surgery.

Boxerman JL, Rogg JM, Donahue JE, Machan JT, Goldman MA, Doberstein CE.

AJR Am J Roentgenol. 2010 Sep;195(3):720-8. doi: 10.2214/AJR.09.4128.

PMID:
20729452
41.

Is Rolandic epilepsy associated with abnormal findings on cranial MRI?

Boxerman JL, Hawash K, Bali B, Clarke T, Rogg J, Pal DK.

Epilepsy Res. 2007 Jul;75(2-3):180-5.

42.
44.

Attenuated myocardial vasodilator response in patients with hypertensive hypertrophy revealed by oxygenation-dependent magnetic resonance imaging.

Beache GM, Herzka DA, Boxerman JL, Post WS, Gupta SN, Faranesh AZ, Solaiyappan M, Bottomley PA, Weiss JL, Shapiro EP, Hill MN.

Circulation. 2001 Sep 11;104(11):1214-7.

PMID:
11551869
45.

Nontraumatic osteonecrosis: MR perfusion imaging evaluation in an experimental model.

Kawamoto S, Shirai N, Strandberg JD, Boxerman JL, Bluemke DA.

Acad Radiol. 2000 Feb;7(2):83-93.

PMID:
10730163
46.

NMR imaging of changes in vascular morphology due to tumor angiogenesis.

Dennie J, Mandeville JB, Boxerman JL, Packard SD, Rosen BR, Weisskoff RM.

Magn Reson Med. 1998 Dec;40(6):793-9.

PMID:
9840821
47.

In vivo measurement of T*2 and field inhomogeneity maps in the human heart at 1.5 T.

Reeder SB, Faranesh AZ, Boxerman JL, McVeigh ER.

Magn Reson Med. 1998 Jun;39(6):988-98.

48.

Advanced MR imaging techniques for evaluation of the heart and great vessels.

Boxerman JL, Mosher TJ, McVeigh ER, Atalar E, Lima JA, Bluemke DA.

Radiographics. 1998 May-Jun;18(3):543-64. Review.

PMID:
9599382
49.

Segmented K-space cine breath-hold cardiovascular MR imaging: Part 2. Evaluation of aortic vasculopathy.

Bluemke DA, Boxerman JL, Mosher T, Lima JA.

AJR Am J Roentgenol. 1997 Aug;169(2):401-7. No abstract available.

PMID:
9242743
50.

Segmented K-space cine breath-hold cardiovascular MR imaging: Part 1. Principles and technique.

Bluemke DA, Boxerman JL, Atalar E, McVeigh ER.

AJR Am J Roentgenol. 1997 Aug;169(2):395-400. No abstract available.

Supplemental Content

Loading ...
Support Center